ASCO 2022 Meeting Report — Breast Cancer

Key trials in breast cancer management

The 2022 American Society of Clinical Oncology (ASCO) annual meeting, held in Chicago June 3–7, highlighted important advances in cancer research. Here, Editor-in-Chief Dr. William Gradishar focuses on key trials in breast cancer. Meeting abstracts can be viewed in the ASCO meeting library.

TRASTUZUMAB DERUXTECAN IN HER2-LOW ADVANCED BREAST CANCER

By far the most impactful presentation at ASCO 2022 was DESTINY-Breast04, reported by Modi and colleagues (abstract LBA3). Previously, the decision to use HER2-targeted therapy in either the early or late stage was based on a binary decision: HER2-positive or HER2-negative. HER2-positive status was defined as immunohistochemistry (IHC)2+ if fluorescent in situ hybridization (FISH)-positive or IHC3+ …

Author

William J. Gradishar, MD

Disclosures

Consultant/Advisory BoardLilly; AstraZeneca; Gilead

Grant/Research SupportBreast Cancer Research Foundation

Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment

Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)